

# Cihan YurdaydÄ±n

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4990492/publications.pdf>

Version: 2024-02-01

128  
papers

7,474  
citations

57719

44  
h-index

54882

84  
g-index

175  
all docs

175  
docs citations

175  
times ranked

4883  
citing authors

| #  | ARTICLE   | IF   | CITATIONS |
|----|---|------|-----------|
| 1  | Peginterferon Alfa-2a Alone, Lamivudine Alone, and the Two in Combination in Patients with HBeAg-Negative Chronic Hepatitis B. <i>New England Journal of Medicine</i> , 2004, 351, 1206-1217.                               | 13.9 | 1,082     |
| 2  | Hepatitis B virus surface antigen levels: A guide to sustained response to peginterferon alfa-2a in HBeAg-negative chronic hepatitis B. <i>Hepatology</i> , 2009, 49, 1141-1150.  | 3.6  | 418       |
| 3  | Peginterferon plus Adefovir versus Either Drug Alone for Hepatitis Delta. <i>New England Journal of Medicine</i> , 2011, 364, 322-331.  | 13.9 | 401       |
| 4  | Entecavir for Treatment of Lamivudine-Refractory, HBeAg-Positive Chronic Hepatitis B. <i>Gastroenterology</i> , 2006, 130, 2039-2049.   | 0.6  | 391       |
| 5  | PAGE-B predicts the risk of developing hepatocellular carcinoma in Caucasians with chronic hepatitis B on 5-year antiviral therapy. <i>Journal of Hepatology</i> , 2016, 64, 800-806.                                       | 1.8  | 358       |
| 6  | The risk of hepatocellular carcinoma decreases after the first 5 years of entecavir or tenofovir in Caucasians with chronic hepatitis B. <i>Hepatology</i> , 2017, 66, 1444-1453.   | 3.6  | 239       |
| 7  | Late HDV RNA relapse after peginterferon alpha-based therapy of chronic hepatitis delta. <i>Hepatology</i> , 2014, 60, 87-97.   | 3.6  | 234       |
| 8  | Oral prenylation inhibition with lonafarnib in chronic hepatitis D infection: a proof-of-concept randomised, double-blind, placebo-controlled phase 2A trial. <i>Lancet Infectious Diseases</i> , The, 2015, 15, 1167-1174. | 4.6  | 216       |
| 9  | Entecavir therapy for lamivudine-refractory chronic hepatitis B: Improved virologic, biochemical, and serology outcomes through 96 weeks. <i>Hepatology</i> , 2008, 48, 99-108.   | 3.6  | 173       |
| 10 | Hepatic encephalopathy in thioacetamide-induced acute liver failure in rats: Characterization of an improved model and study of amino acid-ergic neurotransmission. <i>Hepatology</i> , 1989, 9, 594-601.                   | 3.6  | 161       |
| 11 | Incidence and predictors of hepatocellular carcinoma in Caucasian chronic hepatitis B patients receiving entecavir or tenofovir. <i>Journal of Hepatology</i> , 2015, 62, 363-370.  | 1.8  | 138       |
| 12 | Hepatitis B surface antigen levels: association with 5-year response to peginterferon alfa-2a in hepatitis B e-antigen-negative patients. <i>Hepatology International</i> , 2013, 7, 88-97.                                 | 1.9  | 136       |
| 13 | Peginterferon alfa-2a plus tenofovir disoproxil fumarate for hepatitis D (HIDIT-II): a randomised, placebo controlled, phase 2 trial. <i>Lancet Infectious Diseases</i> , The, 2019, 19, 275-286.                           | 4.6  | 128       |
| 14 | Natural history and treatment of chronic delta hepatitis. <i>Journal of Viral Hepatitis</i> , 2010, 17, 749-756.  | 1.0  | 125       |
| 15 | Optimizing lonafarnib treatment for the management of chronic delta hepatitis: The LOWR HDV study. <i>Hepatology</i> , 2018, 67, 1224-1236.   | 3.6  | 117       |
| 16 | Treatment of chronic delta hepatitis with lamivudine vs lamivudine+interferon vs interferon. <i>Journal of Viral Hepatitis</i> , 2008, 15, 314-321.   | 1.0  | 115       |
| 17 | Age and Sex but Not ATP7B Genotype Effectively Influence the Clinical Phenotype of Wilson Disease. <i>Hepatology</i> , 2019, 69, 1464-1476.   | 3.6  | 110       |
| 18 | Famciclovir treatment of chronic delta hepatitis. <i>Journal of Hepatology</i> , 2002, 37, 266-271.   | 1.8  | 103       |

| #  | ARTICLE   | IF  | CITATIONS |
|----|---|-----|-----------|
| 19 | Quantitative HBsAg and HDV-RNA levels in chronic delta hepatitis. <i>Liver International</i> , 2010, 30, 430-437.   | 1.9 | 96        |
| 20 | Treating chronic hepatitis delta: The need for surrogate markers of treatment efficacy. <i>Journal of Hepatology</i> , 2019, 70, 1008-1015.   | 1.8 | 90        |
| 21 | Response to peginterferon alfa-2a (40KD) in HBeAg-negative CHB: On-treatment kinetics of HBsAg serum levels vary by HBV genotype. <i>Journal of Hepatology</i> , 2013, 59, 1153-1159.             | 1.8 | 88        |
| 22 | Eight-year survival in chronic hepatitis B patients under long-term entecavir or tenofovir therapy is similar to the general population. <i>Journal of Hepatology</i> , 2018, 68, 1129-1136.      | 1.8 | 88        |
| 23 | Seropositivity for delta hepatitis in patients with chronic hepatitis B and liver cirrhosis in Turkey: a meta-analysis. <i>Liver International</i> , 2008, 28, 494-498.                           | 1.9 | 80        |
| 24 | Interferon Treatment Duration in Patients With Chronic Delta Hepatitis and its Effect on the Natural Course of the Disease. <i>Journal of Infectious Diseases</i> , 2018, 217, 1184-1192.         | 1.9 | 78        |
| 25 | Gut bacteria provide precursors of benzodiazepine receptor ligands in a rat model of hepatic encephalopathy. <i>Brain Research</i> , 1995, 679, 42-48.  | 1.1 | 76        |
| 26 | Hepatocellular carcinoma prediction beyond year 5 of oral therapy in a large cohort of Caucasian patients with chronic hepatitis B. <i>Journal of Hepatology</i> , 2020, 72, 1088-1096.           | 1.8 | 75        |
| 27 | Rapid early HDV RNA decline in the peripheral blood but prolonged intrahepatic hepatitis delta antigen persistence after liver transplantation. <i>Journal of Hepatology</i> , 2012, 56, 115-122. | 1.8 | 74        |
| 28 | Clinical and virological heterogeneity of hepatitis delta in different regions worldwide: The Hepatitis Delta International Network (HDIN). <i>Liver International</i> , 2018, 38, 842-850.       | 1.9 | 72        |
| 29 | Similar risk of hepatocellular carcinoma during long-term entecavir or tenofovir therapy in Caucasian patients with chronic hepatitis B. <i>Journal of Hepatology</i> , 2020, 73, 1037-1045.      | 1.8 | 69        |
| 30 | Increased serotonergic and noradrenergic activity in hepatic encephalopathy in rats with thioacetamide-induced acute liver failure. <i>Hepatology</i> , 1990, 12, 695-700.                        | 3.6 | 62        |
| 31 | Thrombophilic gene mutations in cirrhotic patients with portal vein thrombosis. <i>European Journal of Gastroenterology and Hepatology</i> , 2005, 17, 339-343.                                   | 0.8 | 62        |
| 32 | Complete genome sequence and phylogenetic analysis of hepatitis B virus isolated from Turkish patients with chronic HBV infection. <i>Journal of Medical Virology</i> , 2005, 76, 476-481.        | 2.5 | 61        |
| 33 | A pilot study of 2 years of interferon treatment in patients with chronic delta hepatitis. <i>Journal of Viral Hepatitis</i> , 2007, 14, 812-816.   | 1.0 | 61        |
| 34 | Clinical Characteristics of Inflammatory Bowel Disease in Turkey. <i>Journal of Clinical Gastroenterology</i> , 2009, 43, 51-57.  | 1.1 | 59        |
| 35 | Association Between Level of Hepatitis D Virus RNA at Week 24 of Pegylated Interferon Therapy and Outcome. <i>Clinical Gastroenterology and Hepatology</i> , 2015, 13, 2342-2349.e2.              | 2.4 | 57        |
| 36 | Treatment of Chronic Delta Hepatitis. <i>Seminars in Liver Disease</i> , 2012, 32, 237-244.   | 1.8 | 56        |

| #  | ARTICLE   | IF  | CITATIONS |
|----|---|-----|-----------|
| 37 | Risk factors for hepatocellular carcinoma in Turkey. <i>Digestive Diseases and Sciences</i> , 2001, 46, 1022-1028.  | 1.1 | 55        |
| 38 | HBsAg-positive hepatitis delta: virological patterns and clinical long-term outcome. <i>Liver International</i> , 2012, 32, 1415-1425.  | 1.9 | 52        |
| 39 | Tenofovir disoproxil fumarate (TDF) vs. emtricitabine (FTC)/TDF in lamivudine resistant hepatitis B: A 5-year randomised study. <i>Journal of Hepatology</i> , 2017, 66, 11-18.                                     | 1.8 | 52        |
| 40 | Entecavir Treatment of Chronic Hepatitis D. <i>Clinical Infectious Diseases</i> , 2012, 55, 645-650.  | 2.9 | 50        |
| 41 | Anti-HDV IgM as a Marker of Disease Activity in Hepatitis Delta. <i>PLoS ONE</i> , 2014, 9, e101002.  | 1.1 | 50        |
| 42 | Using Chimeric Mice with Humanized Livers to Predict Human Drug Metabolism and a Drug-Drug Interaction. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2013, 344, 388-396.                          | 1.3 | 48        |
| 43 | Ten-year follow-up of a randomized controlled clinical trial in chronic hepatitis delta. <i>Journal of Viral Hepatitis</i> , 2020, 27, 1359-1368.   | 1.0 | 47        |
| 44 | Management of hepatitis C virus infection in the Asia-Pacific region: an update. <i>The Lancet Gastroenterology and Hepatology</i> , 2017, 2, 52-62.  | 3.7 | 45        |
| 45 | A Novel Mutation Pattern Emerging during Lamivudine Treatment Shows Cross-Resistance to Adefovir Dipivoxil Treatment. <i>Antiviral Therapy</i> , 2007, 12, 761-768.   | 0.6 | 45        |
| 46 | Barrett's esophagus: Prevalence and its relationship with dyspeptic symptoms. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2004, 19, 535-540.  | 1.4 | 42        |
| 47 | Hepatitis D virus-specific cytokine responses in patients with chronic hepatitis delta before and during interferon alpha treatment. <i>Liver International</i> , 2011, 31, 1395-1405.                              | 1.9 | 42        |
| 48 | Non-invasive fibrosis score for hepatitis delta. <i>Liver International</i> , 2017, 37, 196-204.  | 1.9 | 42        |
| 49 | A phase 2 dose-finding study of lonafarnib and ritonavir with or without interferon alpha for chronic delta hepatitis. <i>Hepatology</i> , 2022, 75, 1551-1565.   | 3.6 | 41        |
| 50 | Opioid receptor ligands in human hepatic encephalopathy. <i>Journal of Hepatology</i> , 1998, 29, 796-801.  | 1.8 | 35        |
| 51 | The Characteristics and Clinical Outcome of Drug-induced Liver Injury. <i>Journal of Clinical Gastroenterology</i> , 2010, 44, e128-e132.   | 1.1 | 35        |
| 52 | Endoscopic Management of Biliary Parasitic Diseases. <i>Digestive Diseases and Sciences</i> , 2010, 55, 1472-1478.  | 1.1 | 34        |
| 53 | New treatment options for delta virus: Is a cure in sight?. <i>Journal of Viral Hepatitis</i> , 2019, 26, 618-626.  | 1.0 | 33        |
| 54 | Nucleotide divergences in the core promoter and precore region of genotype D hepatitis B virus in patients with persistently elevated or normal ALT levels. <i>Journal of Clinical Virology</i> , 2001, 21, 91-101. | 1.6 | 31        |

| #  | ARTICLE   | IF  | CITATIONS |
|----|---|-----|-----------|
| 55 | Pegylated interferon-alpha plus taurine in treatment of rat liver fibrosis. World Journal of Gastroenterology, 2007, 13, 3237.  | 1.4 | 30        |
| 56 | The case for simplifying and using absolute targets for viral hepatitis elimination goals. Journal of Viral Hepatitis, 2021, 28, 12-19.   | 1.0 | 28        |
| 57 | Nuclear Localization of Hepatitis B Core Antigen and Its Relations to Liver Injury, Hepatocyte Proliferation, and Viral Load. Journal of Clinical Gastroenterology, 2003, 36, 269-272.  | 1.1 | 25        |
| 58 | Anti-Hdv Immunoglobulin M Testing in Hepatitis Delta Revisited: Correlations with Disease Activity and Response to Pegylated Interferon- $\alpha$ 2A Treatment. Antiviral Therapy, 2012, 17, 305-312.   | 0.6 | 25        |
| 59 | Fatigue of cholestasis and the serotonergic neurotransmitter system in the rat. Hepatology, 2005, 41, 731-737.  | 3.6 | 24        |
| 60 | The cost-effectiveness of treating chronic hepatitis B patients in a median endemic and middle income country. European Journal of Health Economics, 2012, 13, 663-676.   | 1.4 | 24        |
| 61 | Effect of HBV-HDV co-infection on HBV-HCC co-recurrence in patients undergoing living donor liver transplantation. Hepatology International, 2020, 14, 869-880.   | 1.9 | 22        |
| 62 | Pegylated interferon-based treatment in patients with advanced liver disease due to chronic delta hepatitis. Turkish Journal of Gastroenterology, 2012, 23, 560-568.  | 0.4 | 22        |
| 63 | Interleukin-28 gene polymorphisms may contribute to HBsAg persistence and the development of HBeAg-negative chronic hepatitis B. Liver International, 2015, 35, 846-853.  | 1.9 | 20        |
| 64 | A one step real time PCR method for the quantification of hepatitis delta virus RNA using an external armored RNA standard and intrinsic internal control. Journal of Clinical Virology, 2014, 60, 11-15.                                     | 1.6 | 19        |
| 65 | Complete genome sequences and phylogenetic analysis of hepatitis delta viruses isolated from nine Turkish patients. Archives of Virology, 2011, 156, 2215-2220.   | 0.9 | 18        |
| 66 | Residual low HDV viraemia is associated HDV RNA relapse after PEG-IFN $\alpha$ -based antiviral treatment of hepatitis delta: Results from the HIDEH study. Liver International, 2021, 41, 295-299.   | 1.9 | 18        |
| 67 | Serum connective tissue markers as predictors of advanced fibrosis in patients with chronic hepatitis B and D. Turkish Journal of Gastroenterology, 2011, 22, 305-314.  | 0.4 | 18        |
| 68 | Hepatitis B core antigen expression pattern reflects the response to anti-viral treatment. Journal of Gastroenterology and Hepatology (Australia), 2006, 21, 977-981.   | 1.4 | 17        |
| 69 | Hepatitis D. Current Treatment Options in Gastroenterology, 2007, 10, 456-463.  | 0.3 | 17        |
| 70 | Molecular characterization of a novel entecavir mutation pattern isolated from a multi-drug refractory patient with chronic hepatitis B infection. Journal of Clinical Virology, 2012, 53, 130-134.   | 1.6 | 16        |
| 71 | Hepatitis C virus genotype distribution in Turkey remains unchanged after a decade: Performance of phylogenetic analysis of the NS5B, E1, and 5'UTR regions in genotyping efficiency. Turkish Journal of Gastroenterology, 2014, 25, 405-410. | 0.4 | 16        |
| 72 | HBcrAg Levels Are Associated With Virological Response to Treatment With Interferon in Patients With Hepatitis Delta. Hepatology Communications, 2022, 6, 480-495.  | 2.0 | 15        |

| #  | ARTICLE   | IF  | CITATIONS |
|----|---|-----|-----------|
| 73 | Factor V Leiden, prothrombin G20210A and MTHFR gene mutations in inflammatory bowel disease. Turkish Journal of Gastroenterology, 2004, 15, 250-2.  | 0.4 | 15        |
| 74 | Remission of severe aplastic anemia associated with hepatitis B virus infection after viral clearance: potential role of lamivudine. Digestive Diseases and Sciences, 2002, 47, 1782-1785.  | 1.1 | 14        |
| 75 | Hepatic outflow obstruction: enhancement patterns of the liver on MR angiography. European Journal of Radiology, 2003, 48, 203-208.   | 1.2 | 13        |
| 76 | Screening for Hemochromatosis in Turkey. Digestive Diseases and Sciences, 2004, 49, 444-449.  | 1.1 | 13        |
| 77 | Regional Epidemiology, Burden, and Management of Hepatitis B Virus in the Middle East. Clinical Liver Disease, 2019, 14, 212-214.   | 1.0 | 13        |
| 78 | The global hepatitis delta virus (HDV) epidemic: what gaps to address in order to mount a public health response?. Archives of Public Health, 2021, 79, 180.  | 1.0 | 13        |
| 79 | Clonal Analysis of the Quasispecies of Antiviral-Resistant HBV Genomes in Patients with Entecavir Resistance during Rescue Treatment and Successful Treatment of Entecavir Resistance with Tenofovir. Antiviral Therapy, 2013, 18, 77-85. | 0.6 | 12        |
| 80 | A Rapid Point-of-Care Test for the Serodiagnosis of Hepatitis Delta Virus Infection. Viruses, 2021, 13, 2371.   | 1.5 | 12        |
| 81 | Portal venous system Evaluation with contrast-enhanced 3D MR portography. Clinical Imaging, 2003, 27, 101-105.  | 0.8 | 11        |
| 82 | Emergence of a Novel Mutation in the FLLA Region of Hepatitis B Virus during Lamivudine Therapy. Antimicrobial Agents and Chemotherapy, 2005, 49, 2618-2624.  | 1.4 | 11        |
| 83 | Efficacy of tenofovir in adefovir-experienced patients compared to treatment-naive patients with chronic hepatitis B. Antiviral Therapy, 2014, 19, 543-550.   | 0.6 | 11        |
| 84 | Aflatoxin exposure in viral hepatitis patients in Turkey. Turkish Journal of Gastroenterology, 2009, 20, 192-197.   | 0.4 | 11        |
| 85 | Lichen planus and HCV infection in Turkish patients. Turkish Journal of Gastroenterology, 2004, 15, 133-6.  | 0.4 | 11        |
| 86 | The central opioid system in liver disease and its complications. , 2001, 16, 79-83.  |     | 10        |
| 87 | Entecavir: a step forward in combating hepatitis B disease. Expert Opinion on Pharmacotherapy, 2008, 9, 3095-3109.  | 0.9 | 10        |
| 88 | Pharmacokinetics and pharmacodynamics modeling of lonafarnib in patients with chronic hepatitis delta virus infection. Hepatology Communications, 2017, 1, 288-292.   | 2.0 | 10        |
| 89 | Recent advances in managing hepatitis D. F1000Research, 2017, 6, 1596.  | 0.8 | 10        |
| 90 | Diagnosis, management and treatment of hepatitis B virus infection: Turkey 2017 Clinical Practice Guidelines. Turkish Journal of Gastroenterology, 2017, 28, 73-83.   | 0.4 | 10        |

| #   | ARTICLE  | IF  | CITATIONS |
|-----|--|-----|-----------|
| 91  | Blood ammonia determination in cirrhosis: Still confusing after all these years?. <i>Hepatology</i> , 2003, 38, 1307-1310.   | 3.6 | 9         |
| 92  | Free circulating nucleic acids in plasma and serum as a novel approach to the use of internal controls in real time PCR based detection. <i>Journal of Virological Methods</i> , 2014, 207, 133-137.   | 1.0 | 9         |
| 93  | Therapy of Delta Hepatitis. <i>Cold Spring Harbor Perspectives in Medicine</i> , 2015, 5, a021543.   | 2.9 | 9         |
| 94  | Hepatitis Delta Virus Epidemiology in the Industrialized World. <i>AIDS Reviews</i> , 2021, 22, 203-212.   | 0.5 | 9         |
| 95  | Lamivudine Treatment in Hbeag-Negative Chronic Hepatitis B Patients with Low Level Viraemia. <i>Antiviral Therapy</i> , 2005, 10, 319-325.   | 0.6 | 9         |
| 96  | Oral Ganciclovir for Treatment of Lamivudine-Resistant Hepatitis B Virus Infection: A Pilot Study. <i>Clinical Infectious Diseases</i> , 2002, 35, 960-965.  | 2.9 | 8         |
| 97  | From viral pathobiology to the treatment of hepatitis B virus infection EASL Monothematic Conference (Istanbul, Turkey, October 6-8, 2005). <i>Journal of Hepatology</i> , 2006, 44, 1186-1195.  | 1.8 | 8         |
| 98  | The role of HBeAg seroconversion in acute exacerbation of liver disease with termination of hepatitis B and D virus infection in a chronic hepatitis D patient during Î±-interferon therapy. <i>European Journal of Gastroenterology and Hepatology</i> , 2003, 15, 819-823. | 0.8 | 7         |
| 99  | A novel pattern (sW195a) in surface gene of HBV DNA due to YSDD (L180M plus M204S) mutation selected during lamivudine therapy and successful treatment with adefovir dipivoxil. <i>Journal of Clinical Virology</i> , 2004, 31, 76-77.                                      | 1.6 | 7         |
| 100 | Role of immunohistochemistry for hepatitis D and hepatitis B virus in hepatitis delta. <i>Liver International</i> , 2014, 34, 1207-1215.   | 1.9 | 7         |
| 101 | Discontinuation of Lamivudine Treatment in HBeAg-Negative Chronic Hepatitis B: A Pilot Study with Long-Term follow-up. <i>Antiviral Therapy</i> , 2017, 22, 559-570.   | 0.6 | 7         |
| 102 | HEV seroprevalence in blood donors in Turkey by two commercial total anti-HEV Ab ELISA kits. <i>Journal of Medical Virology</i> , 2019, 91, 2174-2181.   | 2.5 | 6         |
| 103 | Hepatitis Delta Virus Infection: A Large Burden After All?. <i>Journal of Infectious Diseases</i> , 2020, 221, 1573-1575.  | 1.9 | 6         |
| 104 | 5-hydroxytryptamine release in the anterior hypothalamic and the hippocampal areas of cholestatic rats. <i>Life Sciences</i> , 2006, 78, 1078-1083.  | 2.0 | 5         |
| 105 | Treatment of chronic hepatitis B with telbivudine: wise hepatologists needed in hepatitis B endemic countries where treatment options are limited. <i>Liver International</i> , 2011, 31, 589-591.   | 1.9 | 5         |
| 106 | Manometric assessment of esophageal motor function in patients with primary biliary cirrhosis. <i>European Journal of Internal Medicine</i> , 2014, 25, 230-234.   | 1.0 | 5         |
| 107 | A transient early HBV-DNA increase during PEG-IFNÎ± therapy of hepatitis D indicates loss of infected cells and is associated with HDV-RNA and HBsAg reduction. <i>Journal of Viral Hepatitis</i> , 2021, 28, 410-419.   | 1.0 | 5         |
| 108 | Predictive performance of newer Asian hepatocellular carcinoma risk scores in treated Caucasians with chronic hepatitis B. <i>JHEP Reports</i> , 2021, 3, 100290.  | 2.6 | 5         |

| #   | ARTICLE  | IF  | CITATIONS |
|-----|--|-----|-----------|
| 109 | PPAR-alpha L162V polymorphism in human hepatocellular carcinoma. Turkish Journal of Gastroenterology, 2008, 19, 245-9.   | 0.4 | 5         |
| 110 | Influence of Viral Load and Alanine Aminotransferase on Viral Genetic Heterogeneity in Patients with Chronic Hepatitis C Virus Infection. Intervirology, 2000, 43, 61-66.  | 1.2 | 4         |
| 111 | Peroxisome Proliferator-Activated Receptor $\alpha$ L162V Polymorphism in Nonalcoholic Steatohepatitis and Genotype 1 Hepatitis C Virus-Related Liver Steatosis. Journal of Investigative Medicine, 2005, 53, 353-359. | 0.7 | 4         |
| 112 | Potential proteomic biomarkers in assessing liver fibrosis using SELDI-TOF MS. Turkish Journal of Gastroenterology, 2012, 23, 46-53.   | 0.4 | 4         |
| 113 | Delta hepatitis in Turkey: decreasing but not vanishing and still of concern. Turkish Journal of Gastroenterology, 2006, 17, 74-5.   | 0.4 | 4         |
| 114 | Editorial: natural history of hepatitis delta virus-induced liver disease less severe today but still needs attention. Alimentary Pharmacology and Therapeutics, 2021, 54, 519-520.                                    | 1.9 | 3         |
| 115 | Epidemiology of Hepatitis B Virus in the Middle East. , 2021, , 91-99.   |     | 3         |
| 116 | Percutaneous transhepatic venoplasty: an alternative treatment for Budd-Chiari syndrome. Turkish Journal of Gastroenterology, 2002, 13, 83-8.  | 0.4 | 3         |
| 117 | Effect of inhibition of ornithine decarboxylase activity in a model of acute hepatocellular necrosis. European Journal of Gastroenterology and Hepatology, 1998, 10, 503-508.  | 0.8 | 1         |
| 118 | FRI-175-Frequency, severity and impact of Peg-IFNa-associated flares in HDV infection: Results from the HIDIT-II study. Journal of Hepatology, 2019, 70, e466.   | 1.8 | 1         |
| 119 | Developing New Therapies for Delta Hepatitis: The Race Is On. Hepatology Communications, 2021, 5, 556-558.   | 2.0 | 1         |
| 120 | Determination of Turkish norms of psychometric tests for diagnosing minimal hepatic encephalopathy and proposal of a high sensitive screening test battery. Hepatology International, 2021, 15, 1442-1455.             | 1.9 | 1         |
| 121 | Hereditary pancreatitis: Report of a family from Turkey. Pediatrics International, 1998, 40, 612-615.  | 0.2 | 0         |
| 122 | Future Therapy for Hepatitis B Virus and Hepatitis D Virus. Current Hepatology Reports, 2016, 15, 259-265.   | 0.4 | 0         |
| 123 | SAT-171-HEV seroprevalence in blood donors in Turkey: Comparison of two commercial anti-HEV total Ab ELISA kit. Journal of Hepatology, 2019, 70, e704-e705.  | 1.8 | 0         |
| 124 | Acute HBV/HDV Infection. , 2019, , 67-75.  |     | 0         |
| 125 | Letter to the Editor: Interferon Is Not an Optimal Treatment for Chronic Hepatitis Delta but Needs a Fair Treatment by Us. Hepatology, 2021, 74, 1127-1127.  | 3.6 | 0         |
| 126 | Immunohistochemistry for Viral Hepatitis: Methods and Applications. Biomarkers in Disease, 2017, , 719-733.  | 0.0 | 0         |



| #   | ARTICLE   | IF  | CITATIONS |
|-----|---|-----|-----------|
| 127 | Evaluation of the results of MOTAKK hepatitis C virus RNA genotyping and hepatitis delta virus external quality assessment programs during 2015-2016. Turkish Journal of Gastroenterology, 2019, 30, 957-963. | 0.4 | 0         |
| 128 | P21 expression and its relation to disease activity and hepatocyte proliferation in chronic hepatitis B virus infection. Turkish Journal of Gastroenterology, 2005, 16, 12-6.                                 | 0.4 | 0         |